The estimated Net Worth of Roger M Perlmutter is at least $37.6 Million dollars as of 8 November 2018. Roger Perlmutter owns over 225,443 units of Merck & Co stock worth over $30,501,121 and over the last 16 years he sold MRK stock worth over $0. In addition, he makes $7,098,640 as Executive Vice President and President – Merck Research Laboratories at Merck & Co.

Roger Perlmutter MRK stock SEC Form 4 insider trading

Roger has made over 4 trades of the Merck & Co stock since 2003, according to the Form 4 filled with the SEC. Most recently he exercised 225,443 units of MRK stock worth $10,140,426 on 8 November 2018.

The largest trade he’s ever made was exercising 225,443 units of Merck & Co stock on 8 November 2018 worth over $10,140,426. On average, Roger trades about 8,807 units every 133 days since 2003. As of 8 November 2018 he still owns at least 366,997 units of Merck & Co stock.

You can see the complete history of Roger Perlmutter stock trades at the bottom of the page.

Roger Perlmutter biography

Dr. Roger M. Perlmutter, M.D. Ph.D. is Executive Vice President and President – Merck Research Laboratories of the Company. He is responsible for the Company’s global research and development efforts. Dr. Perlmutter was executive vice president and head of R&D at Amgen Inc. from January 2001 to February 2012. During his tenure, Dr. Perlmutter oversaw the development and subsequent approval of a number of novel biologic and small molecule medicines in the areas of cancer, endocrinology, hematology, inflammation and osteoporosis. Prior to joining Amgen, he was executive vice president of worldwide basic research and preclinical development at Merck. He joined Merck as a senior vice president in February 1997. Before assuming leadership roles in industry, Dr. Perlmutter was a professor in the Departments of Immunology, Biochemistry and Medicine at the University of Washington, where he also served as chairman of the Department of Immunology and was a Howard Hughes Medical Institute investigator. He is a Fellow of the American Academy of Arts and Sciences and an elected Fellow of the American Association for the Advancement of Science. Dr. Perlmutter graduated from Reed College in 1973 and received his M.D. and Ph.D. degrees from Washington University in St. Louis in 1979.

What is the salary of Roger Perlmutter?

As the Executive Vice President and President – Merck Research Laboratories of Merck & Co, the total compensation of Roger Perlmutter at Merck & Co is $7,098,640. There are 1 executives at Merck & Co getting paid more, with Kenneth Frazier having the highest compensation of $20,934,500.

How old is Roger Perlmutter?

Roger Perlmutter is 67, he’s been the Executive Vice President and President – Merck Research Laboratories of Merck & Co since 2013. There are 3 older and 18 younger executives at Merck & Co. The oldest executive at Merck & Co., Inc. is Thomas Cech, 72, who is the Independent Director.

What’s Roger Perlmutter’s mailing address?

Roger’s mailing address filed with the SEC is ONE MERCK DRIVE, , WHITEHOUSE STATION, NJ, 08889-0100.

Insider trading at Merck & Co

Over the last 10 years, insiders at Merck & Co have traded over $53,837,709 worth of Merck & Co stock and bought 47,800 units worth $1,519,400 . The most active insider traders include Wendell P Weeks, Kenneth C Frazier, and Adam H Schechter. On average, Merck & Co executives and independent directors trade stock every 15 days with the average trade being worth of $3,440,102. The most recent stock trade was executed by Steven Mizell on 30 October 2019, trading 4,574 units of MRK stock currently worth $379,276.

What does Merck & Co do?

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species, which it sells to veterinarians, distributors, and animal producers. The Healthcare Services segment offers services and solutions that focus on engagement, health analytics, and clinical services to improve the value of care delivered to patients. The Alliances segment includes results from the Company’s relationship with AstraZeneca LP related to sales of Nexium and Prilosec. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

What does Merck & Co’s logo look like?

Complete history of Roger Perlmutter stock trades at Amgen and Merck & Co

Merck & Co executives and stock owners

Merck & Co executives and other stock owners filed with the SEC include:

• Kenneth Frazier, Chairman of the Board, President, Chief Executive Officer
• Roger Perlmutter, Executive Vice President, President – Merck Research Laboratories
• Robert Davis, Executive Vice President, Global Services, Chief Financial Officer
• Jennifer Zachary, Executive Vice President, General Counsel
• Peter Wendell, Independent Director
• Wendell Weeks, Independent Director
• Rochelle Lazarus, Independent Director
• Leslie Brun, Lead Independent Director
• Paul Rothman, Independent Director
• Pamela Craig, Independent Director
• Thomas Cech, Independent Director
• Patricia Russo, Independent Director
• Thomas Glocer, Independent Director
• Inge Thulin, Independent Director
• Mary Coe, Independent Director
• Rita Karachun, Senior Vice President Finance – Global Controller
• Julie Gerberding, Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health
• Richard DeLuca, Executive Vice President, President – Merck Animal Health
• Frank Clyburn, Executive Vice President, Chief Commercial Officer
• Sanat Chattopadhyay, Executive Vice President and President – Merck Manufacturing Division
• Michael Nally, Executive Vice President, Chief Marketing Officer
• Jim Scholefield, Executive Vice President, Chief Information and Digital Officer
• Steven Mizell, Executive Vice President, Chief Human Resources Officer, Human Resources
• Craig B. Thompson, Director
• Adam H Schechter, EVP & Pres-Global Human Health
• Adele D Ambrose, V-P & Chief Com. Officer
• Clark Golestani, EVP & Chief Info Officer
• John H Noseworthy, Director
• Michael J Holston, EVP, Chief Ethics & Compl Ofcr
• Carlos E Represas, Director
• C Robert Kidder, Director
• Weir Mirian M Graddick, Exec. V-P, Human Resources
• Ashley Watson, SVP Chief Ethics & Com Officer
• James H Scholefield, EVP,Chief Info&Digital Officer
• Michael Fleming, SVP Chief Ethics & Com Officer
• William B Jr Harrison, Director
• Michael Rosenblatt, Exec V-P & Chief Med Officer
• John Canan, Senior V-P, Controller
• Stanley F Barshay, Exec V-P Consumer Health Care
• Willie A Deese, Exec. V-P and Pres., MMD
• Anne M Tatlock, Director
• Samuel O Md Thier, Director
• Mervyn Turner, Chief Strategy Officer
• Willam N Kelley, Director
• Richard S Iii Bowles, Exe V-P & Chief Compl Officer
• Peter S Kim, Exec. V-P and Pres., MRL
• Thomas E Shenk, Director
• Bridgette P Heller, Exe.VP & Pres.Con.Hlth.Care
• Raul E Kohan, Exe V-P & Pres, Animal Health
• Steven F Goldstone, Director
• Harry R Jacobson, Director
• Richard T Clark, Chairman, President and CEO
• Peter N Kellogg, Exec. V.P. & C.F.O
• Bruce N Kuhlik, Exec. V.P. and General Counsel
• Cuong V Do, EVP & Chief Strategy Officer
• J Chris Scalet, Exe. VP, Global Services & CIO